New research led by UCLA Health revealed that Black patients with Huntington’s disease in the U.S. and Canada received their diagnoses, on average, one year later compared to White patients after symptoms first appear.
PepGen earns FDA fast track designation for myotonic dystrophy type 1 candidate – Pharmaceutical Technology
Share this article PepGen develops therapies for severe neuromuscular diseases. Image credit: Shutterstock/MacroEcon. The US Food and Drug Administration (FDA) has granted fast track designation